CopyMark Law Group
4.9/5
Drawing for MEDCLUERX

USPTO serial 87155650

MEDCLUERX

Reviewed by CopyMark Law Group

Reg. 5308043Status 702Renewal
Filing date
Status date
Registration date
Oct 10, 2017
Examiner
JOHNSON, DONALD
Law office
TMEG LAW OFFICE 104

What this means

This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.

Status 702: Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use.

Need help with MEDCLUERX?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $399*

Plus Government fees of $650

Trademark Monitoring(312) 319-4460
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Start a new application
(312) 319-4460

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Rosanne Yang

Rosanne Yang InfoLawGroup LLP41 W. South StreetWorthington, OH 43085United States

Goods and services

ClassDescriptionStatusFirst use
044Genetic testing for medical purposes; medical testing for diagnostic or treatment purposes; medical testing services, namely, medical tests that measure, analyze, and interpret genes of patients; personalized medical testing services, namely, pharmacogenomics testing services for diagnostic or treatment purposes; providing medical information, consultancy, and advisory services; medical information services, namely, preparation and generation of reports for the foregoing testing services through proprietary software applications; pharmacogenomics testing for diagnostic or treatment services; providing medical information to pathologists, physicians, and other healthcare practitioners with respect to tests, test results, test analysis, test trends, test effectiveness, test advisability, test selection, test ordering, test ordering management, test ordering procedures, test ordering efficiency, test ordering effectiveness, medical condition, health condition, and diagnosis in the fields of pathology, genetics, and pharmacogenomicsACTIVEJan 12, 2017

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 10, 2026REM2COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED—
Feb 20, 2026TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Feb 20, 2026ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Feb 20, 2026REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Feb 20, 2026CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Feb 20, 2026COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Feb 16, 2024NA85NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED—
Feb 16, 2024C15AREGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.—
Feb 16, 2024APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Aug 29, 2023E815TEAS SECTION 8 & 15 RECEIVED—
Oct 10, 2022REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Apr 22, 2019ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 22, 2019REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
May 10, 2018CORVREVIEW OF CORRESPONDENCE COMPLETE - POWER OF ATTORNEY ENTERED—
May 2, 2018EWAFTEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS—
Apr 30, 2018TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Oct 10, 2017R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Sep 8, 2017SUNANOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED—
Sep 7, 2017CNPRALLOWED PRINCIPAL REGISTER - SOU ACCEPTED—
Aug 29, 2017SUPCSTATEMENT OF USE PROCESSING COMPLETE—
Aug 22, 2017AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Jul 31, 2017IUAFUSE AMENDMENT FILED—
Jul 31, 2017EISUTEAS STATEMENT OF USE RECEIVEDThe applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action.
Mar 14, 2017NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Jan 17, 2017NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jan 17, 2017PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Dec 28, 2016NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Dec 9, 2016CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Dec 8, 2016DOCKASSIGNED TO EXAMINER—
Sep 7, 2016MPMKNOTICE OF PSEUDO MARK E-MAILED—
Sep 6, 2016NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Sep 2, 2016NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance